> SIRT > Legal information




Selective Internal Radiation Therapy Experts Group
c/o ipse Communication GmbH
Albrechtstraße 14 B
10117 Berlin


Martina Dörmann
Tel. +49 (0)30 288846-51
Fax +49 (0)30 288846-46


Responsible party pursuant to Section 55 Para. 2 of the State Broadcasting and Telemedia Services Treaty and responsible party pursuant to the Press Law:


Martina Dörmann
Managing Director ipse Communication GmbH
Albrechtstraße 14 B
10117 Berlin


Tel. +49 (0)30 288846-0
Fax +49 (0)30 288846-46


District court Charlottenburg / Berlin B
VAT ID DE 208291685


The Selective Internal Radiation Therapy Experts Group, is supported by an unrestricted educational grant from SIRTeX Medical Europe GmbH.




The following conditions and all applicable laws apply to the use of this website. By accessing this site, you acknowledge the following conditions without restriction.


The data and text published on this website is provided free of charge and is intended for information purposes only. The use of this information does not imply any commercial relationship between you and ipse Communication GmbH. Hyperlinks on this website may lead to other website that are not maintained by ipse Communication GmbH. ipse Communication GmbH accepts no liability or responsibility for the content of these websites. Any link to an external website does not constitute a guarantee of its content or the services it provides. Any use of the information provided on this website, or on other websites to which this website links, is at the user’s own risk.


ipse Communication GmbH operates this website in Germany. The conditions of use and all legal processes are based on German law. If any legal proceedings are brought against ipse Communication GmbH, the decision regarding which jurisdiction shall apply shall be made by ipse Communication GmbH. ipse Communication GmbH will with great probability choose Germany as the place of jurisdiction, regardless of which country you are in, or from which country you have visited the website.


Concept, design and programming


Systeam Plus oHG, Berlin
Tel. +49 (0)30 398016-16



More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: